A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene versus Placebo in Reducing Symptoms of Knee OA

Panda SK, Nirvanashetty S, Parachur VA, Mohanty N, Swain T · BioMed Research International

Total WOMAC, its subscales and VAS all improved significantly versus placebo, with no treatment-related adverse events and unchanged biochemistry, haematology and urinalysis.

Population

Adults aged 40-75 with ACR-criteria knee osteoarthritis for over 3 months, India

Intervention

Curene (Aquasome-formulated curcuminoids) 500 mg once daily

Comparator

Placebo

Limitations

n=50, single centre, and run by the formulation's manufacturer (OmniActive/Ocius); duration is short and the trial reports no structural or biomarker endpoint.